Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia Comanche Biopharma closes oversubscribed $75 Million Series B financing to advance first treatment targeting a root cause of preeclampsia.

AAFA Is Proud to Support Major Legislative Package Addressing America’s Black Maternal Health Crisis Washington D.C., Feb. 08, 2021 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is proud to endorse the Black Maternal Health Momnibus Act of 2021. It is a legislative package...